Indeed, the SFI-induced MYC signature is able to predict prostate cancer lethality, independently of the degree of tumour differentiation and patient obesity status and the robustness of this finding was validated in four independent cohorts. Here, MYC is linked to obesity due to melanocortin 4 receptor deficiency.